To assess the persistence of hepatitis G virus (HGV) infection and its association with liver disease, HGV RNA was assessed in the most recent serum sample for 246 long-term injecting drug users (IDUs) and in prior specimens for those found HGV RNA -positive. HGV RNA was detected at the most recent visit in 38 (15.4%). For 31 (82%), HGV RNA was also found at all prior visits occurring a median of 6.1 years earlier. HGV-positive IDUs were younger and had fewer years of drug use, suggesting that HGV RNA had previously been cleared. Serial samples from 29 shortterm IDUs were then assessed. HGV RNA was detected in 9 (31%) of 29 short-term IDUs, and 5 (56%) of the 9 HGV infections cleared. No differences were detected in serum levels of liver-related enzymes among HGV RNA -positive and -negative participants (P ú .20). HGV infection is not associated with hepatic inflammation. HGV clearance occurs after many acute infections but uncommonly in persons who remain RNA-positive years after exposure.
Five well-characterized viruses principally cause inflamma-11, 12] and in association with fulminant non-A -E hepatitis [13, 14] . Thus, HGV occurs in humans, may be parenterally tion of human liver and are designated hepatitis viruses A -E. Despite the application of sensitive assays for these agents, the transmitted, and has been associated with hepatitis. However, the magnitude of infection in at-risk populations, the frequency etiology of 10% -20% of acute posttransfusion and communityacquired hepatitis remains unknown [1, 2] . In addition, there and duration of viral persistence, and the extent to which HGV causes liver inflammation remain unknown. The aim of this is no apparent cause for 2% -10% of chronic hepatitis cases [3, 4] . A viral etiology for non-A -E hepatitis was suggested study was to evaluate HGV persistence and its association with HCV infection and liver disease. by the induction of hepatitis in tamarins inoculated with plasma from a patient with non-A -E hepatitis (whose initials were G.B.) and subsequent cross-challenge experiments using tamarin acute-phase plasma [5] . Recently, a candidate non-A -E Methods agent was identified, and viral isolates were named GB virus Study participants. In 1989, a cohort of 2946 IDUs was re-C (GBV-C) [6] and hepatitis G virus (HGV) [7] .
cruited at the Johns Hopkins School of Hygiene and Public Health Phylogenetic studies of multiple HGV and GBV-C isolates in Baltimore [15] [16] [17] . At enrollment, 89% of participants were indicate they are variants of the same species of the Flavivirus African American and 81% were men. The mean age and duration family, distinct from other members such as hepatitis C virus of drug use were 34 years and 13 years, respectively. Antibodies (HCV) and GB viruses A and B [6 -8] . For expedience, the to HCV were detected in 89%, while 24% were human immunodevirus will be referred to subsequently as HGV.
ficiency virus (HIV)-positive and 80% had a marker of hepatitis HGV RNA has been found in plasma from community-B virus (HBV) infection [18, 19] .
acquired and transfusion-associated non-A -E hepatitis patients
Cross-sectional investigation. To address optimally the aims of this investigation (evaluate HGV persistence and its correlation sample were stored at 070ЊC and later tested for HGV RNA. Liver enzyme measures were not available for 56 participants without a study visit since the onset of liver enzyme testing in 1995. Since demographic factors and sexual practices were most extensively and consistently assessed at enrollment, these data were used to assess HGV correlates. Drug-using practices were evaluated for the 6-month period before the HGV testing visit.
HCV antibody was assessed at enrollment by use of a secondgeneration ELISA (Ortho Diagnostics, Raritan, NJ) and, if negative, reassessed at subsequent visits. Prior study of HCV among these IDUs demonstrated HCV RNA in at least 95% of HCV antibody-positive participants, indicating that antibody status is a reliable marker of ongoing HCV infection and that it may be compared with HGV RNA data [20] .
Detection and quantitation of HGV RNA. Total nucleic acids were extracted from 100 mL of serum sample by use of guanidium thiocyanate-phenol-chloroform [21, 22] . Purified and pelleted nucleic acid was suspended in 20 mL of diethyl polycarbonatetreated water: 10 mL for the detection of HGV RNA and the remainder for RNA quantitation. Reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out by use of an RNA PCR Kit (Perkin-Elmer Cetus, Norwalk, CT) and PCR Carry-over Prevention Kit (Perkin-Elmer Cetus) with primers (0.4 mM each) Figure 1 . Selection of study populations from original cohort of of the putative NS5 region of the HGV genome: sense (CGAATGinjection drug users (IDUs). Cross-sectional study (performed first) AGTCAGAGGACGGGGTAT) and antisense (CTCTTTGTGwas based on most recent study visit. Long-term IDUs were studied, GTAGTAGCCGAGAGAT). Forty-five cycles of PCR (94ЊC for since highest occurrence was expected in these subjects. Total no.
1 min, 55ЊC for 1 min, and 72ЊC for 1 min for each cycle) were studied (n Å 246) is less than sum of candidates, since serum speciperformed, followed by the extension reaction at 72ЊC for 7 min. mens were not available for all and since some criteria were not PCR products were analyzed by dot blot hybridization with a 32 Pmutually exclusive. † Samples collected at prior visits (look-back) were labeled oligonucleotide probe (TCGGTTACTGAGAGCAGCtested for all subjects HGV RNA -positive and random sample of TCAGATGAG). The sensitivity of this assay system was 1 HGV Ç25% of HGV RNA -negative IDUs. ‡ After preliminary analysis of results of cross-sectional and look-back studies, serial specimens were RNA copy/reaction, corresponding to Ç20 copies/mL of serum. , and forward). ALT, alanine aminotransferase. 10 4 copies/50 mL) was done by RT-PCR, dot blot hybridization of standards and samples, and counting of radioactivity of each portion by AMBIS Radioanalytic Imaging System (AMBIS, San Diego). The total radioactive counts of each standard were plotted Because serum specimens were not available for all selected partiagainst the HGV RNA copy number to establish a standard curve; cipants and since some criteria were not mutually exclusive, the the radioactive count and the copy number were correlated linearly actual number studied (n Å 246) was less than the sum of the in a range of 10 1 -10 4 copies/mL (P õ .05; r ú .9). The copy candidates. This group of 246 participants will be designated as number of each sample was determined by comparison with the long-term IDUs.
standard curve. In this study, the concentration of HGV RNA in Look-back and prospective investigation. To assess HGV serum is expressed as copies per milliliter. Laboratory personnel RNA persistence, serial serum samples were tested. First, a lookwere blinded to participant identifiers and sample selection criteria. back investigation based on cross-sectional test results of most Statistical methods. Descriptive methods (frequency, univarirecent visits of long-term IDUs was conducted. From all HGVate, and box plots) were used to examine the distributions of catepositive subjects, the first available (enrollment) and 2 intermedigorical and continuous variables. Statistical comparisons of associate specimens were tested. In addition, from a randomly selected ations between dichotomous variables were made by using x 2 or sample of 25% of HGV-negative participants, the first available Fisher's exact tests. Medians of continuous variables from separate sample was tested and, if positive, intermediate samples were subgroups were compared by nonparametric (Wilcoxon rank sum assessed. To confirm observations made in the cross-sectional or Kruskal-Wallis) test procedures. Correlations between continuand look-back investigation, an additional group of 29 IDUs was ous variables were assessed by using the Spearman correlation then randomly selected from IDUs in the total cohort who had coefficient. The independent association of HGV RNA and sig-õ2 years of drug use at enrollment. For these 29 participants, nificant correlates from univariate analyses was assessed by logisdesignated short-term IDUs, HGV status was determined in their tic regression, using an inclusion criterion of P õ .05. The likelienrollment sample, the last available sample, and 2 intermediate hood-based estimates and 95% confidence intervals (CIs) for the specimens (total n Å 107).
corresponding antilog of the parameters in the logistic model are Timing of measurements. Liver enzyme testing was done within 24 h of serum procurement. Aliquots of the same serum presented. senting those with serum ALT levels ú100 U/L and those õ40 U/L. HGV RNA concentrations (median, 12,589 copies/mL; sectional investigation of long-term IDUs. At enrollment into the cohort, the median age of the 246 study participants was range, 10 -100,000) were not significantly correlated with serum ALT (r Å 0.30, P Å .324) or AST (r Å 0.202, P Å 35.8 years, 89.4% were African-American, and 85.8% were men. The median duration of injecting drug use was 17.9 years, .508) levels. NOTE. Data are from prospective follow-up of 29 short-term IDUs (õ2 years of injecting at enrollment in ALIVE Study in 1988), not included in cross-sectional study, and followed for 3 or 4 visits.
* At enrollment (ú90%) or second visit. † Overall HGV test pattern prospectively determined from initial visit and consisting of 3 -4 visits over corresponding follow-up time.
‡ Calculated as years between initial and most recent visits, summed over all participants for that group.
HGV RNA persistence. Among 38 long-term IDUs who from the most recent visit of the long-term IDUs (n Å 243).
A significantly higher rate of HGV RNA was detected among were HGV RNA -positive at their most recent visit, 31 (81.6%) younger IDUs (P õ .001 for trend) (figure 2), and HGV RNA were positive at all earlier visits, representing 165.0 personwas more prevalent among IDUs with shorter durations of drug years of cumulative follow-up (median, 5.9 years/subject) (tause. This association was similar to that found for HBsAg, the ble 2). The remaining 7 participants observed over 36.8 personmarker of ongoing HBV infection, which was 4-fold more years had a prior negative sample, suggesting they were newly frequent in those õ25 years of age (23%) than in IDUs ú40 infected. By use of a survival function, 80% of participants years (6%) (P Å .04). In contrast, the prevalence of anti-HCV were estimated to have been HGV RNA -positive 5 years beincreased sharply with age. fore their most recent visit (95% CI, 66% -93%). From a ranAmong high-risk drug-using behaviors, only sharing of needom sample of long-term IDUs who were HGV-negative at dles was significantly associated with HGV RNA, whereas their most recent visit, earlier specimens were available for 47 duration of drug use, active drug use, needle-sharing, and cowho were observed over a total of 285.0 person-years; 42 (89%) caine use were all associated with HCV infection (table 4) . of 47 were consistently negative for HGV RNA, while prior There were no significant correlations with high-risk sexual HGV infection was noted in 5 (11%) followed for 33.8 cumulabehaviors such as having a history of a sexually transmitted tive person-years. There were no instances of intermittent HGV disease, male homosexual contact, or exchanging sex for infection (RNA-positive, then -negative, then -positive) over money or drugs. The median number of sex partners was simithe entire look-back examination, totaling 486.9 person-years lar among HGV RNA -positive IDUs (10.5 persons) and HGV of observation.
RNA -negative participants (10.0 persons, P ú .10). Among the 85 long-term IDUs in the look-back evaluation, the median age of the 7 with new infections (25 years) was lower than for 31 with persistent positive infections (33 years), 5 who cleared (35 years), and 42 with persistent negative infections (37 years) (P Å .008, Kruskal-Wallis test for multiple group comparisons).
Short-term IDUs. To evaluate possible differences in the occurrence and persistence of HGV RNA in subjects in whom the probable duration of infection was shorter, HGV RNA was then assessed in 4 serial samples prospectively collected from 29 short-term IDUs (õ2 years of drug use at enrollment). At enrollment, 7 (24.1%) short-term IDUs were HGV RNApositive, and 2 new HGV infections were noted over 150.4 years of follow-up, an incidence of 1.45 per 100 person-years (95% CI, 0.36 -5.81) (table 3). Of the 9 short-term IDUs who were HGV RNA -positive at some time point, 5 (55.6%) cleared their infection over 5.8 years of follow-up, a rate of In a study of transfusion-associated hepatitis, HGV RNA was RNA status was not associated with HIV (OR, 0.9; 95% CI, found in 3 (23%) of 13 patients negative for other markers of 0.4 -2.0) or HBsAg (OR, 1.5; 95% CI, 0.5 -4.4). After adknown hepatitis viruses (non-A-E) [10]. Conversely, the majorjusting for age by use of logistic regression, only age õ37 ity (77%) of patients with transfusion-associated non-A-E hepayears (lowest tertile) (OR, 10.5; 95% CI, 2.8 -39.1) and sharing titis were HGV RNA-negative. In addition, quantitation of needles in the preceding 6 months (OR, 3.5; 95% CI, 1.3 -plasma HGV RNA, an index of viral replication, did not correlate 9.4) remained strongly associated with HGV RNA status. The with ALT levels [10] . In another study, HGV RNA was detected association of HGV RNA with HCV infection became nonsigin 4 patients (9%) with acute community-acquired non-A-E nificant (P ú .20).
hepatitis but in even a greater proportion of patients with acute hepatitis A (25%), hepatitis B (32%), and hepatitis C (20%) [9] . These data and those in the current study suggest that HGV does Discussion not cause significant chronic liver disease. However, more studies that include histologic evaluation of liver tissue are needed to The principal aims of this investigation were to determine establish whether HGV replicates in human liver and causes if HGV infections occurred among a cohort at high risk for chronic hepatitis, cirrhosis, and hepatocellular carcinoma. parenterally transmitted diseases and to evaluate HGV RNA More than 80% of HCV infections persist [2] . Thus, among persistence and its correlation with HCV and biochemical persons with continuous HCV exposure, the prevalence of markers of liver disease.
HCV increases sharply with age and indices of exposure (in-HGV RNA was detected in 15.4% of long-term IDUs. Howcluding duration and frequency of drug use), as was found in ever, there was no association between HGV RNA or HGV this study [18] . In contrast, this study demonstrated that ongo-RNA levels and biochemical markers of liver inflammation.
ing HGV infection was more frequent among IDUs who were Even among the IDUs without HCV or ongoing HBV infecyounger and had shorter durations of drug use, suggesting that tions (or both), there was no evidence that HGV caused significant liver inflammation. In contrast, levels of ALT, AST, and HGV is a less persistent virus than HCV. This hypothesis was / 9d31$$se10 07-24-97 10:41:46 jinfa UC: J Infect JID 1997;176 (September) HGV Infection among Drug Users supported by observing that more than half of HGV infections rate of HGV RNA persistence among some long-term IDUs, there is no biochemical evidence that HGV causes significant among short-term IDUs were transient and by a similar observation made in a cross-sectional study of IDUs [11] .
liver disease or affects the course of HCV coinfection. The higher rate of HGV RNA clearance observed in short-term Eighty-two percent of long-term IDUs who were HGV RNA -positive at their most recent visit were also previously IDUs suggests that clearance occurs more frequently just after infection and less frequently once infection is established. Appositive. This finding may appear to contradict the hypothesis that HGV infection commonly clears. However, since the meplication of a serologic marker of HGV exposure should document more precisely the incidence of and recovery from HGV dian duration of drug use at enrollment in the long-term group was 18 years, many of these participants could have been ininfection. Additional studies are also needed to clarify the location of HGV replication and what, if any, human diseases it fected previously and cleared HGV RNA prior to being tested in this study. This explanation seems likely, since the median causes. age of those who were persistently HGV-negative was higher than that of those persistently positive, while those with new
